DPx adds more biologics capacity to its contract manufacturing business
Picks up Gallus Pharma, whose plants are in St. Louis and Princeton, NJ
As Big Pharma gets bigger through acquisitions (like the recently announced Roche-InterMune deal), contract development and manufacturing orgnizations (CDMOs) are keeping pace. The latest merger is DPx Holdings’ purchase of Gallus Pharmaceuticals, headquartered in St. Louis. Gallus will be folded into the Patheon unit of DPx, which itself came together through the merger of Patheon and parts of DSM Fine Chemicals this spring.
Last year, Gallus had acquired Laureate Pharmaceuticals (which brought the Princeton facility). DSM brought a recent acquisition, Banner PharmaCaps, into the DPx unit. Private equity firms are driving some of this merging; Gallus is owned by Ridegmont Equity Partners; DPx is jointly owned by DSM, the Dutch chemicals and industrial products giant, and JLL Partners, with JLL as majority owner.
AT the time of the DPx formation, employment measured 8,000, in 24 locations worldwide. Gallus brings an additional 370 employees.
LogiPharma Unpacked: Highlights, Key Insights, and the Road to 2025
October 16th 2024In this special post-show episode, we sit down with Ryan Portela, Head of Production for LogiPharma, to reflect on the highlights and key takeaways from this year’s event. From attendee feedback to the most impactful sessions, Ryan shares insider insights and discusses how the momentum from 2024 will continue to shape the future of pharma supply chains. Plus, get a sneak peek into the exciting plans for LogiPharma's 20th Anniversary in 2025.
Reimagining Closed-Loop Marketing Strategies for Pharma Companies
November 21st 2024The pharmaceutical industry is evolving, and so are the strategies needed to connect with healthcare professionals. Closed-loop marketing (CLM) has become essential in delivering personalized, data-driven engagement that resonates with physicians and improves key outcomes, such as enhancing patient care, increasing
Maximize Pharma’s Potential with AI-Ready Data for Commercial Excellence
November 21st 2024As the pharmaceutical industry embraces the power of AI, having data that’s large, diverse, and well-structured is critical for driving innovation and improving outcomes. Ensuring your data is AI-ready and can be used with more advanced solutions enables your teams to make informed strategic decisions, predict trends, enhance customer engagements and drive overall strategy.
